Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 18, 2022, the Board of Directors of Sigilon Therapeutics, Inc. (the
"Company") appointed Josias Fantato De Pontes as the Company's Acting Chief
Financial Officer and Treasurer. Upon his appointment, Mr. Pontes replaced Dr.
Rogerio Vivaldi, M.D., as the Company's principal financial officer. Mr. Pontes
will continue to serve as the Company's principal accounting officer.
Mr. Pontes, age 55, previously served as the Company's Vice President, Head of
Finance since November 2019. Prior to joining the Company, Mr. Pontes was Senior
Director, Financial Planning and Analysis at Zafgen, Inc., a biotechnology
company, from December 2017 to August 2019. From 2016 to 2018, Mr. Pontes
served as Senior Director, Accounting Reporting and Consolidation and Financial
Planning and Analysis at Juniper Pharmaceuticals, Inc. Mr. Pontes also worked
in various finance roles of increasing responsibility at Genzyme, most recently
serving as the Senior Director of Finance and Controller of the Rare Diseases
business unit. He holds an MBA from Ohio University and a B.A. in Accounting
from the FECAP University in Sao Paulo, Brazil.
There is no family relationship between Mr. Pontes and any director or executive
officer of the Company and Mr. Pontes has no direct or indirect material
interest required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On February 22, 2022, the Company announced in a press release that Qing Sarah
Yuan, Ph.D. is expected to join the Company as its Chief Technical Operations
Officer, effective March 7, 2022. A copy of this press release is attached to
this Current Report on Form 8-K as Exhibit 99.1.
The information in Item 7.01 of this Form 8 K (including Exhibit 99.1 attached
hereto) is being furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any filing by the Company, under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filling.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
Press Release Issued by Sigilon Therapeutics, Inc. on February 22,
99.1 2022
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)
© Edgar Online, source Glimpses